Barbara De Moerloose
- Hematology top 1%
- Acute Myeloid Leukemia Research 49
- Chronic Myeloid Leukemia Treatments 16
- Genetics top 5%
-
- Acute Lymphoblastic Leukemia research 49
- Cancer Research top 10%
- Oncology top 10%
- CAR-T cell therapy research 12
- Neutropenia and Cancer Infections 12
- Drug Transport and Resistance Mechanisms 11
-
- Childhood Cancer Survivors' Quality of Life 14
-
- Neuroblastoma Research and Treatments 13
- Co-authors
- Yves BenoîtCatharina DhoogeJan PhilippéGeneviève LaureysTim LammensPieter Van VlierbergheSteven GoossensKatrien Swerts
- Partner nations
- BelgiumNetherlandsFrance
In The Last Decade
Barbara De Moerloose
117 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 94
- Hematology 644
- Genetics 241
- Public Health, Environmental and Occupational Health 510
- Cancer Research 254
- Oncology 454
Countries citing papers authored by Barbara De Moerloose
This map shows the geographic impact of Barbara De Moerloose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara De Moerloose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara De Moerloose more than expected).
Fields of papers citing papers by Barbara De Moerloose
This network shows the impact of papers produced by Barbara De Moerloose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara De Moerloose. The network helps show where Barbara De Moerloose may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Barbara De Moerloose, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 16 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 3 | |
| 5 | 2022 | 9 | |
| 6 | 2022 | 82 | |
| 7 | 2022 | 13 | |
| 8 | 2022 | 4 | |
| 9 | 2021 | 39 | |
| 10 | 2020 | 10 | |
| 11 | The ION-Ghent guidelines for the management of immune related adverse events (irAE's) | 2017 | 1 |
| 12 | 2017 | 6 | |
| 13 | PEG-asparaginase in treatment of childhood acute lymphoblastic leukemia | 2013 | 0 |
| 14 | Musculoskeletal manifestations in children with acute lymphoblastic leukaemia | 2012 | 2 |
| 15 | Treatment of refractory T-lymphoblastic leukaemia and lymphoma with nelarabine | 2011 | 1 |
| 16 | Therapeutic efficacy and safety of transfusion of pathogen-inactivated platelets tot pediatric patients | 2006 | 4 |
| 17 | Imaging with Technetium-99m sestamibi does not predict drug resistance or outcome in childhood neuroblastoma | 2001 | 0 |
| 18 | 99mTc-MIBI imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein | 1999 | 1 |
| 19 | Immunocytochemical and flow cytometric analysis of P-glycoprotein in childhood ALL | 1996 | 0 |
| 20 | Expression of the multidrug transporter, P-glycoprotein, in childhood leukemia: a prospective clinical study | 1994 | 6 |
About Barbara De Moerloose
Barbara De Moerloose is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics, having authored 127 papers that have together received 1.7k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (49 papers), Acute Lymphoblastic Leukemia research (49 papers), Chronic Myeloid Leukemia Treatments (16 papers), Childhood Cancer Survivors' Quality of Life (14 papers), Neuroblastoma Research and Treatments (13 papers), CAR-T cell therapy research (12 papers), Neutropenia and Cancer Infections (12 papers) and Drug Transport and Resistance Mechanisms (11 papers). The work is most often cited by research in Hematology (644 citations), Genetics (241 citations) and Public Health, Environmental and Occupational Health (510 citations). Barbara De Moerloose has collaborated with scholars based in Belgium, Netherlands and France. Frequent co-authors include Yves Benoît, Catharina Dhooge, Jan Philippé, Geneviève Laureys, Tim Lammens, Pieter Van Vlierberghe, Steven Goossens, Katrien Swerts, Henrik Hasle and Veerle Mondelaers. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.